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DURING THE LAST DECADE, only three major im-
munosuppressants have been used extensively for 
whole organ transplantation, namely azathioprine, 
prednisone, and heterologous antilymphocyte glob-
ulin. None of these agents is sufficiently potent to 
permit consistent success when used alone in human 
beings. Consequently, the drugs have been admin-
istered in the double combination of azathioprine 
and prednisone or more recently in a triple com-
bination of all three agents. 
This article was undertaken to describe our 
experience with cyclophosphamide, a fourth major 
immunosuppressive drug which was given from the 
outset instead of azathioprine to 40 whole organ 
recipients and which was used to replace aza-
thioprine at varying times after transplantation in 
another 54 patients. The results have shown cyclo-
phosphamide to be equivalent to azathioprine in its 
therapeutic role and effectiveness. 
METHODS 
Cyclophosphamide from Outset 
Material. There were 33, six, and one recipients, 
respectively, of 37 renal, six hepa tic, and one cardiac 
homografts. The liver and heart transplants were 
used to replace the diseased organs in the ortho-
topic location, whereas most of the kidneys were 
placed heterotopically in the inferior portion of 
either the right or left extraperitoneal space. When 
the kidneys were obtained from related donors, 
bilateral nephrectomy and splenectomy were per-
formed through a separate incision in the upper 
part of the abdomen on the same day as the trans-
plantation. With cadaveric renal transplantation, 
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the host kidneys or spleen usually was not dis-
turbed. 
Transplantation was not restricted to prime can-
didates in that 22 of the 40 patients fell into one, 
or more, putative high risk categories including age 
greater than 45 or less than 17 years, gastroin-
testinal ulceration, pancreatitis, lupus erythema-
tosus, and a recent history of malignant neoplasia. 
Moreover, six of the 33 kidney recipients were 
entered into the cyclophosphamide series at the 
time of retransplantation after having rejected a 
first kidney at some past time. 
Good histocompatibility matching was not re-
quired. For example, the consanguineous kidney 
donors had an A or B match with the recipients, as 
defined by Mickey and his associates (8), in only 
four of 18 instances. C, D, and E matches were 
present in another 13, and in one, the presence of 
antigraft antibodies caused the designation of F 
match. The 18 familial kidney donors included 11 
siblings, six parents, and one aunt. 
Within the 26 donor-recipient pairs of the 24 
cadaveric renal, hepatic, and c,!-rdiac transplants, 
there were no good human leukocyte antigen 
(HL-A) matches. One human leukocyte antigen 
was mismatched in six instances. In the other 20, 
either two, three, or all four of the antigens were 
incompatible. 
Immunosuppression. Treatment was adapted from 
the triple drug regimen which has been used at our 
institution since 1966 (16) except that cyclo-
phosphamide was administered in place of aza-
thioprine (15). The patients receiving consan-
guineous kidneys were given cyclophosphamide 
orally for three to nine days before operation, 
starting with 0.3 to 2.3 (mean 1.1) milligrams per 
kilogram per day and concluding with larger doses 
of 2.5 to 5.8 (mean 3.6) milligrams per kilogram 
per day on the day before and the day of trans-
plantation. During the same pretreatment interval, 
daily intramuscular injections were given of horse 
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antilymphocyte globulin that had leuko-agglutinin 
and lymphocytotoxin titers of 1 :4,000 to 1 :8,000 
and 1 :4,000 to 1 :16,000, respectively, and a protein 
concentration of 5.0 to 7.2 grams per 100 milli-
liters. Finally, prednisone was given orally in pre-
operative doses of 0.4 to 1.2 (mean 0.71) milligrams 
per kilogram per day. 
For the cadaveric renal, hepatic, and cardiac 
transplantations, pretreatment was not feasible, 
and immunosuppression was usually begun on the 
day of operation. Under these conditions, the 
initial dose of cyclophosphamide was 1.0 to 4.4 
(mean 2.9) milligrams pcr kilogram by intravenous 
infusion over three hours, usually during the oper-
ation. Prednisone and antilymphocyte globulin were 
also started during or just after operation. 
After transplantation, the protocol called for a 
decreasing number of antilymphocyte globulin in-
jections after two weeks and for adjustments in 
prednisone dosage, especially after the first few 
weeks, according to the difficulty encountered with 
rejection. The average daily doses of cyclophospha-
mide used postoperatively started at 2 or 3 milli-
grams per kilogram, but eventually, these usually 
had to be reduced to considerably less than 1 
milligram per kilogram to avoid leukopenia. The 
drug was given orally when possible, but in the 
absence of alimentation, it was administered intra-
venously each day in 5 per cent glucose in water 
over approximately three hours. 
Azathioprine Control Studies 
The results in the cyclophosphamide series were 
compared with those obtained in the three months 
from December 1970 to mid-March 1971 during 
which period a triple drug program of azathioprine, 
prednisone, and horse antilymphocyte globulin, of 
comparable potency to that used in the subsequent 
cyclophosphamide series, was used as primary 
treatment. The control patients included nine and 
two recipients of cadaveric kidneys and livers, 
respectively. Two of these patients had a single 
human leukocyte antigen mismatch with the donor, 
but the other nine had incompatibilities of two, 
three, or four antigens. The donors in the 20 con-
sanguineous renal transplantations were ten siblings 
and ten parents. Within the sibling subgroup, there 
were four A matches connoting the favorable con-
dition of double haplotype identity of the human 
leukocyte antigen system. 
Histopathologic Studies 
Organs recovered at autopsy or transplant 
nephrectomy from both the cyclophosphamide and 
aza thioprine series were fixed in formalin and 
stained with hematoxylin and eosin, periodic acid-
Schiff, Weigert's for elastic counterstained with 
hematoxylin and van Gieson, methyl green-
pyronine, and Sudan III. The liver sections were 
also stained for reticulin fibers by Gordon and 
Sweet's silver impregnation method and for iron by 
Perls' Prussian blue method. 
Delayed Cyclophosphamide 
A total of 54 pa tien ts were taken off main tenance 
immunosuppressive therapy with azathioprine and 
were given cyclophosphamide instead. In four 
recipients of orthotopic liver transplants, the change 
was made from nine to 35 months after trans-
plantation. A patient given a cardiac homograft 20 
months earlier also had the substitution. 
In addition, 49 renal recipients were given 
cyclophosphamide in place of aza thioprine from one 
and one-half to 94 months postoperatively. In 11 
patients, hepatotoxicity or other side effects of 
azathioprine, including drug fever, were suspected. 
Nine more patients were switched to cyclophos-
phamide because of the serologic diagnosis of 
chronic Australia antigenemia even though ab-
normalities in liver function were either minimal or 
absent. The switch in therapy in the other 29 
patients was made in the hope of eventually main-
taining graft function with smaller dosages of 
prednisone. Consequently, reductions in the daily 
quantities of steroids were usually made shortly 
after the institution of the cyclophosphamide. 
In replacing aza thioprine with cyclophosphamide, 
the same precautions were taken as when cyclo-
phosphamide was used from the beginning. Fre-
quent white blood cell counts were obtained, and 
appropriate dosage adjustments were made with 
any indication of impending leukopenia. Eventu-
ally, the typical patient was found to tolerate two-
thirds the dosage of cyclophosphamide per kilogram 
as had previously been possible with azathioprine. 
RESULTS 
Cyclophosphamide from Outset 
Intrafamilial renal transplantation. All 18 of the 
recipients primarily treated with cyclophosphamide 
are still alive. However, two of the 18 consan-
guineous kidneys failed because of hyperacute re-
jection and were removed within minutes, or hours, 
after transplantation. The serum of one of these 
patients had preformed cytotoxic antibodies with 
antigraft specificity, but this unfavorable condition 
was not demonstrable in the other patient. Both 
patients were subsequently given cadaveric kidneys 
and will be considered in the next section. 
It was possible to evaluate the cyclophosphamide 
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FIG. 1. The first 60 days after the transplantation of a kidney from a mother to her 14 year old 
daughter. The rejection crisis after a week Was the most severe observed in the intrafamilial 
cyclophosphamide series, with the exception of two hyperacute rejections. However, it was easily 
and completely reversed. Note that leukopenia was never produced by the daily doses of cyclo-
phosphamide that were usually between 0.5 to 1 milligram per kilogram per day. ALG, Horse 
antilymphocyte globulin; BUN, blood urea nitrogen level; CCr, creatinine clearance; WBC, 
white blood cell count; and arrow, 625 milligrams of methyl prednisolone intravenously. 
regimen in the other 16 recipients of related kid-
neys. All have had a satisfactory result with follow-
up periods that are now two to six months. Re-
jection has never been diagnosed in seven patients, 
it occurred in a mild form in seven, and it was 
severe but eventually reversed in the other two 
(Fig. 1). The relations between the quantities of 
cyclophosphamide and prednisone versus graft 
function and white blood cell count after one and 
two postoperative months are summarized for the 
16 patients in Figure 2. 
In the control series of 20 intrafamilial renal re-
cipients treated with triple drug immunosuppres-
sion including azathioprine, there was one hyper-
acute rejection by a patient who did not have 
preformed antibodies. A subsequent attempt at 
cadaveric transplantation using the triple drug 
cyclophosphamide regimen resulted in the same 
complication, necessitating a probably permanent 
return to chronic dialysis. 
Three of the remaining 19 patients under aza-
thioprine therapy died of widespread infections for 
an over-all mortality rate of 15 per cent. Nine of 
the 19 recipients escaped rejection altogether. The 
other eight and two underwent mild and severe 
rejection episodes, respectively. The average pat-
tern of recovery, as reflected in steroid requirement 
and graft function, was essentially the same as in 
the cyclophosphamide series, the principal differ-
ence being that the dosage of azathioprine per kilo-
gram of body weight needed to achieve a com-
parable effect on the white blood cell count was 
approximately 2.5 times that of cyclophosphamide 
(Fig. 2). 
Cadaveric renal transplantation. Among the 17 pa-
tients in the cyclophosphamide series, there were 
12 who were undergoing transplantation for the 
first time. Eight or 67 per cent of the 12 still have 
good function of their original homografts after two 
to 4.5 months (average 3.7 months). One of the 
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FIG. 2. Drug doses and laboratory measurements at the 
end of one and two months in patients given either cyclo-
phosphamide or azathioprine. All these recipients of kidneys 
donated by blood relatives were also treated with pred-
nisone and horse antilymphocyte globulin. The p values are 
noted only for differences that were statistically significant. 
remaining four died 68 days postoperatively of an 
Aspergillus brain abscess following a protracted 
and incompletely controlled rejection. The other 
three recipients rejected their grafts which either 
became nonfunctional or were removed after one 
to nine weeks. Retransplantation was performed in 
two of these three patients with a good result four 
and two months later. The third patient is still on 
hemodialysis awaiting the retransplantation pro-
cedure. 
The other five cadaveric renal recipients treated 
with cyclophosphamide were at high risk from im-
munologic sensitization in that two, two, and one 
of these patients had destroyed their first grafts by 
hyperacute, acute, and chronic rejection, respec-
tively. After retransplantation under the cyclo-
phosphamide regimen, three of the five secondary 
transplants failed, one because of hyperacute rejec-
tion and two more because the recipients died of 
cecal ulceration and gram-negative septicemia or 
Pneumocystis carinii pneumonitis, respectively. 
The other two grafts are functioning satisfactorily 
after four and six months. 
There were nine control patients treated with a 
triple drug regimen contammg azathioprine in-
stead of cyclophosphamide. Only two of the group 
were undergoing primary transplantation. One has 
had an excellent result after nine months. The 
other rejected his kidney within a few days but then 
had successful retransplantation under cyclophos-
phamide treatment as previously has been de-
scribed. 
The other seven recipients were in the high risk 
retransplantation category. One died of diffuse 
interstitial pneumonitis and a second destroyed her 
kidney by hyperacute rejection. The other five still 
have variable life-sustaining function of their grafts 
after six to nine months. 
The recipients of cadaveric renal transplants 
were such a heterogenous group and underwent so 
many retransplan ta tions that comparisons of steroid 
dosages, graft function, and other parameters were 
not meaningful in the cyclophosphamide versus 
azathioprine-treated patients. 
Cadaveric liver transplantation. Two of the six pa-
tients died of cholangitis, liver abscesses, and bac-
teremia which were secondary to biliary obstruc-
tion. In both patients, cholecystoduodenostomy had 
been performed after ligation of the distal part of 
the common bilc duct. The obstruction was at, or 
near, the junction of the cystic and common bile 
ducts. The other four patients, aged three, four, 15, 
and 52 years, are alive from one and one-half to six 
months postoperatively. The liver replacement was 
for biliary atresia in two recipients and for Wilson's 
disease and a hepatic hemangioendothelial sarcoma 
in the third and fourth. Two of the surviving pa-
tients have not had a rejection, although one of 
them had transient deterioration of hepatic func-
tion coincident with the development of Australia 
antigenemia (Fig. 3). The other two recipients had 
moderately severe rejections which were eventually 
controlled (Fig. 4). 
The two control patients received orthotopic 
livers under triple drug therapy including azathio-
prine. A 12 year old girl with chronic aggressive 
hepatitis had the same type of cystic duct obstruc-
tion described in the preceding paragraph which 
led to death nine weeks after transplantation de-
spite secondary operative correction. The other re-
cipient who was aged 44 years died of a brain stem 
hemorrhage four and one-half weeks after liver re-
placement for postnecrotic cirrhosis. 
Cadaveric heart transplantation. A 39 year old recip-
ient became remittently hypotensive beginning 27 
days after transplantation for atherosclerotic coro-
nary artery disease, coincident with multiple other 
signs of rejection. He had a cardiac arrest and died 
32 days after operation. 
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FIG. 3. Triple drug therapy with cyclophosphamide, prednisone, and horse antilymphocyte 
globulin in a 15 year old male who had an orthotopic liver transplantation for Wilson's disease. 
Rejection has never been diagnosed postoperatively. The temporary deterioration in hepatic 
function in the second postoperative month was accompanied by Australia antigenemia and 
consequently was thought to be a manifestation of serum hepatitis. ALG, Horse antilymphocyte 
globulin; CP, complement fixation; SGa T, serum glutamic oxalacetic transaminase in interna-
tional units; and WBC, white blood cell count. 
Drug Toxicity 
The incidence of several complications was com-
pared in the renal recipients treated primarily with 
cyclophosphamide and in those given azathioprine 
from the outset. The results were converted to per-
centages and expressed in graphic form (Fig. 5), 
including only patients for whom full information 
was available for at least two postoperative months. 
Leukopenia severe enough to require the omis-
sion of the radiomimetic drugs for at least three 
consecutive days occurred somewhat more fre-
quently in the azathioprine group (Fig. 5). This 
usually connoted white blood cell counts of less 
than 5,000 per cubic millimeter. Thrombocyto-
penia was also sporadically observed in both groups, 
but the finding frequently seemed more attribut-
able to treatment with antilymphocyte globulin 
than to the cytotoxic drugs. 
The incidence of serious infections was similar in 
the cyclophosphamide and azathioprine series (Fig. 
5). Moreover, the nature of the responsible micro-
organisrns tended to be comparable with a heavy 
representation of fungi, viruses, and protozoa of 
normally low pathogenicity. 
Anorexia and diarrhea are well known complica-
tions of high dosage treatment with cyclophos-
phamide. In the low quantities given in this study, 
such complaints were uncommon. There was only 
one patient with intractable diarrhea, and at au-
topsy, its cause was found to be a large cecal ulcer. 
The incidence of gastrointestinal complaints was 
almost exactly the same in the azathioprine series 
(Fig. 5). 
Abnormalities of liver function were considered 
major if the transaminase level exceeded 250 in-
ternational units on more than two occasions, if 
jaundice developed, and if there was depression of 
protein synthesis, as measured by a serum albumin 
concentration of less than 3 grams per 100 milli-
liters, or persistent depressions of the prothrombin 
time. There was one example of liver malfunction 
in a cyclophosphamide-treated patient in whom 
acute serum hepatitis, Australia antigen positive, 
developed. The azathioprine series contained one 
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FIG. 4. The early course of a 52 year old male who had total liver replacement as treatment 
for a hemangioendothelial sarcoma. This rare liver tumor usually causes death from fulminating 
hepatic failure in a few weeks or months, but it does not commonly metastasize. After trans-
plantation, there was a severe rejection crisis. The protracted thrombocytopenia postopera-
tively is often noted after liver transplantation and is probably due to thrombocyte sequestra-
tion in the homograft. ALG, Horse antilymphocyte globulin; SGO T, serum glutamic oxalacetic 
transaminase in international units; and arrow, 625 milligrams of methyl prednisolone in-
travenously. 
recipient with major hepatic dysfunction and three 
with minor abnormalities (Fig. 5). None of these 
latter recipients was Australia antigen positive. 
One patient became bald shortly after a cyclo-
phosphamide-induced bout of leukopenia. Her 
hair returned completely after discontinuance of 
cyclophosphamide and the substitution of azathio-
prine. 
Histopathologic Studies 
Compared with those in the azathioprine studies, 
the renal and hepatic transplants from the cyclo-
phosphamide-treated patients did not have any 
particularly distinguishing gross or microscopic fea-
tures. 
The kidneys of two of the cyclophosphamide-
treated patients and three of the azathioprine-
treated patients were normal except for a little 
tubular epithelial damage and slight interstitial 
mononuclear cell infiltration. Features compatible 
with hyperacute rejection having occurred were 
present in three of the cyclophosphamide group and 
two of the azathioprine group. There was a mod-
erate amount of intimal thickening of the inter-
lobular and arcuate arteries in the kidneys of one 
of the cyclophosphamide-treated patients and in 
one of the azathioprine-treated patients. The only 
differences between the two groups were that one 
kidney in the azathioprine-treated group showed 
acute cellular rejection and had ruptured and that 
the kidneys of two of the cyclophosphamide-trea ted 
patients showed areas of hemorrhagic necrosis in 
the cortex and venous thrombosis as well as arterial 
intimal thickening and interstitial mononuclear 
cell infiltration. 
Three hepatic homografts, two from the cyclo-
phosphamide and one from the azathioprine series, 
were examined microscopically. Specimens were 
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not available from the other azathioprine-treated 
recipient who died. The three livers showed no 
evidence of rejection but had all the features of 
partial obstruction of the large biliary ducts. 
Cholangitis was present in two of the organs, one 
from each series. 
Focal mononuclear cell infiltration was present 
in the myocardium of the cyclophosphamide-
treated patient who received a cardiac transplant, 
but the coronary arteries and their branches were 
normal. 
Delayed Cyclophosphamide 
After renal transplantation. The 49 patients were 
one and one-half to 94 months after a primary or in 
some cases a repeat transplantation. The substitu-
tion of cyclophosphamide and azathioprine was 
almost never the only alteration in management. 
For example, upward or downward adjustments in 
steroids were made freely as it was thought indi-
cated (Fig. 6). Moreover, a number of other less 
well defined variables could not be controlled at all 
or even measured. Consequently, the events follow-
ing cyclophosphamide substitution, whether in the 
direction of improvement or deterioration, could 
not necessarily be attributed to the change in treat-
ment. 
Ten recipients had the cyclophosphamide sub-
stitution in the first three postoperative months 
during the time when therapy with horse anti-
lymphocyte globulin was still in effect. Two of 
these ten patients had diffuse interstitial pneumo-
nitis due to the protozoan Pneumocystis carinii, and 
a third had a through and through staphylococcal 
infection of the transplant wound. All three died. 
The fatal course of the pre-existing infections was 
not affected by the substitution of cyclophospha-
mide for azathioprine or by the later discontinu-
ance of all immunosuppression. 
The reasons for the cyclophosphamide substitu-
tion in the first three months were subnormal 
homograft function, a persistent fever, and difficulty 
with azathioprine dosage control in five, one, and 
one additional recipients, respectively. Homograft 
function has remained essentially the same in all 
seven patients for three to five months. The child 
with high fever became normothermic within a few 
days after the administration of azathioprine was 
stopped and has remained so. 
Among the 39 patients with cyclophosphamide 
substitution after three months, all were either al-
ready off treatment with antilymphocyte globulin 
or else the globulin was stopped not long after the 
drug change. The only one who died was a 40 year 
old man with severe hepatic failure due to chronic 
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FIG. 5. Incidence of toxicity in the first two months of 
treatment of renal homograft recipients with cyclophospha-
mide versus azathioprine. At the dosages used, there was 
little obvious difference between the two agents. The one 
patient under cyclophosphamide therapy in whom major 
hepatic dysfunction developed had a proved attack of acute 
serum hepatitis, Australia antigen positive. 
aggressive hepatitis. Renal transplantation had 
been performed three and one-half years pre-
viously. His serum had contained antibodies against 
Australia antigen for the two preceding years. He 
died 45 days after changing to the cyclophos-
phamide. The alteration in treatment had no ob-
vious effect on his course. 
Three of the 39 renal recipients changed to cy-
clophosphamide later than three months after 
transplantation had subsequent deterioration of 
homograft function. However, in one, the kidney 
already was gradually failing after two years, a 
deterioration that has slowly continued during two 
and one-half months of cyclophosphamide treat-
ment. The other two patients were of greater in-
terest since excellent renal function preceded the 
drug substitution. The first recipient had been 
given five homografts, the last one from a cadaveric 
donor four and one-half months previously. Shortly 
after the conversion to cyclophosphamide, horse 
antilymphocyte globulin was stopped, and in addi-
tion, the prednisone dosage was significantly 
reduced. Renal failure recurred within three 
months which was not reversed by a switch back to 
azathioprine and by a large increase in steroids. 
The other patient was similar except that the sub-
stitution of cyclophosphamide was 16 months after 
transplantation of an uncle's kidney, long after dis-
continuance of antilymphocyte globulin therapy. 
Within three months, the blood urea nitrogen level 
rose from 11 to 125 milligrams per cent. Resump-
tion of azathioprine and increases in prednisone 
have not restored good function. 
The other 35 kidney recipients switched from 
azathioprine to cyclophosphamide have maintained 
their pre-existing renal homograft function during 
the one and one-half to nine months of follow-up 
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FIG. 6. The consecutive use of azathioprine and cyclophosphamide after cadaveric renal homo-
transplantation in a 20 year old male is charted. The change to cyclophosphamide was made be-
cause of dissatisfaction with the early postoperative course. There was slow improvement in the 
subsequent convalescence, but, retrospectively, there is no reason to believe that this might not 
have occurred even without making the drug switch. The globulin injections were daily for ten 
days, every other day for 20 days, and twice a week until they were discontinued because of 
anaphylactic reactions. ALG, Horse antilymphocyte globulin; BUN, blood urea nitrogen level; 
CCr, creatinine clearance; and WBC, white blood cell count. 
study (Figs. 6 and 7). During this period, 18 of the 
35 patients have had reductions of 10 to 35 (mean 
20) per cent in their daily steroid dosage. Since the 
same type of late relaxation of prednisone therapy 
had been observed with other immunosuppressive 
regimens which contain azathioprine, the steroid 
reductions could not be attributed with assurance 
to the advent of cyclophosphamide. 
The commonest specific indication to replace 
azathioprine with cyclophosphamide was suspected 
hepatotoxicity. Prior to the drug change, there were 
five kidney recipients who had major liver malfunc-
tion as defined earlier by jaundice, persistent trans-
aminasemia, or evidence of impaired protein syn-
thesis. Excluding the patient who died of hepatic 
failure within a few weeks, liver function improved 
in all the others (Fig. 7). 
After hepatic and cardiac transplantation. One of the 
four liver recipients had a dramatic, immediate fall 
in the serum transaminase level after the switch 
from azathioprine to cyclophosphamide, but within 
two months, these returned to the pre-existing level. 
The courses of the other three liver and one cardiac 
recipients have remained stable and satisfactory. 
DISCUSSION 
Although the principal use of cyclophosphamide 
in clinical medicine has been for cancer chemo-
therapy, its immunosuppressive qualities have been 
increasingly exploited. It has been used by Mon-
crieff (9), White (19), Fosdick (3), Novack (10), 
Greenspan (6), Buckley 0), Wong (20), Seah 
(14), and Laros (7) and their associates for .the 
treatment of autoimmune disorders as diverse as 
the nephrotic syndrome, proliferative glomeru-
lonephritis, rheumatoid arthritis, Wegener's granu-
lomatosis, lethal midline granuloma, peripheral 
uveitis, ocular inflammatory disease, systemic lupus 
erythematosus, and thrombocytopenic purpura. 
Even in the field of whole organ transplantation, 
cyclophosphamide had an early trial but under cir-
cumstances which did not permit its value to be 
fully appreciated. Almost a decade ago, Goodwin 
(5), Parsons (11), and Fox (4) and their asso-
ciates reported the use of cyclophosphamide, alone 
or in combination with prednisone, in a total of 
nine kidney recipients. Although rejection was con-
trolled in several patients, a high incidence of bone 
marrow depression and lethal infections dis-
couraged further efforts. When cyclophosphamide 
was proved by Reams (12) as well as by subsequent 
investigators to be worthless for the prevention of 
renal homograft rejection in the dog, the seal of 
disapproval was nearly complete even though the 
poor results in dogs were probably due to a species 
peculiarity not relevant to human beings (15). 
Eventually, Santos and his associates (13) and a 
few others who gave large dosages of cyclophos-
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FIG. 7. The course of a 17 year old female in whom azathioprine was stopped because of the sus-
picion of hepatotoxicity. Multiple Australia antigen tests for serum hepatitis were negative. Note 
the recession of jaundice after the substitution of cyclophosphamide for azathioprine. BUN, blood 
urea nitrogen level; sea T, serum glutamic oxalacetic transaminase in international units; and 
WBC, white blood cell count. 
phamide in an attempt to induce tolerance to bone 
marrow grafts remained the only spokesmen for the 
potential usefulness of this agent after any type of 
human transplantation procedure. 
In retrospect, the reputation for toxicity ac-
quired by cyclophosphamide in the early years of 
its use in cancer chemotherapy as well as for trans-
plantation was the consequence of heavy dosage. 
In addition to bone marrow depression and infec-
tion, common complications included anorexia and 
other gastrointestinal disturbances, hemorrhagic 
cystitis, and alopecia. By giving smaller main-
tenance dosages which seldom exceeded 0.5 milli-
gram per kilogram of body weight per day, these 
side reactions were reduced to an acceptable mini-
mum in this study. To permit precise management, 
the standard 50 milligram tablets which cannot 
be accurately divided even in halves had to be 
repackaged in our local pharmacy into capsules 
containing 5, 10, and 25 milligrams. 
Using the small dosages of cyclophosphamide, 
the effectiveness of the drug in preventing rejection 
of whole organ homografts was evaluated under 
two circumstances. To one group of recipients, cy-
clophosphamide was given from the outset in place 
of azathioprine as part of a triple drug regimen that 
also included prednisone and horse antilymphocyte 
globulin. Patient and organ survival; graft function 
and histopathologic condition; steroid require-
ment; and toxic and infectious complications were 
not essentially different from a companion series 
of recipients who were given azathioprine instead. 
With cyclophosphamide treatment, the results 
were slightly but not significantly better with intra-
familial renal transplantation. In addition, there 
was improvement in the results after orthotopic 
liver transplantation. However, there was a similar 
slight balancing superiority under azathioprine 
protection in the recipients of cadaveric kidney 
grafts. 
In the second group of patients, azathioprine 
was discontinued at varying times after transplan-
tation and replaced with cyclophosphamide. It was 
not possible in the vast majority of patients to iden-
tifyeither subsequent deterioration or improvement 
in homograft function. Even in those patients who 
had alterations in function, these changes were 
usually attributable to adjustments in steroid dos-
age. A valid generalization was that patients doing 
well before changing from azathioprine to cyclo-
phosphamide did well afterward. In contrast, those 
with pre-existing infection or graft deterioration 
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that had developed under azathioprine were not 
benefited merely by instituting cyclophosphamide. 
Instead, the outcome was dependent upon the suc-
cess with which antibiotics were used or with which 
prednisone dosages were manipulated. 
The remarkably comparable effectiveness of cy-
clophosphamide and azathioprine under both 
these general conditions of clinical testing is of some 
theoretic interest since their pharmacologic actions 
are thought to be dissimilar. Cyclophosphamide, an 
alkylating agent, has been said by Wheeler (18) to 
exert its primary cytotoxic effect by blocking the G2 
phase of the cell cycle. In contrast, the purine ana-
logue azathioprine has been shown by Elion (2) to 
inhibit deoxyribonucleic acid production during 
the S phase ofthe cycle. Yet, the events of rejection, 
its reversibility, and eventually the feasibility, in 
many instances, to lighten maintenance immuno-
suppression have not been perceptibly different 
with either of the drugs as compared with the other. 
The newest observations with cyclophosphamide 
provide one more example of how nonspecific im-
munosuppression in the continuous presence of 
homograft antigen can lead by undefined mecha-
nisms to a characteristic cycle of recovery and 
eventual graft acceptance, which implies a pro-
found alteration in the host-graft relationship (17). 
The reliability with which this can be achieved 
with the use of either azathioprine or cyclophospha-
mide in the triple drug therapeutic regimen has 
become so great with intrafamilial renal transplan-
tation that a high degree of benefit can be achieved 
with 80 per cent, or more, of such operations 
with, or without, discriminating histocompatibility 
matching. In contrast, the cycle of graft acceptance 
cannot be so readily negotiated after transplanta-
tion from unrelated donors, making cadaveric 
transplantation a more dangerous and unpre-
dictable undertaking under any conditions of 
treatment known today, as was illustrated by the 
results in both our cyclophosphamide and aza-
thioprine series. 
From a practical point of view, the fact that cy-
clophosphamide and azathioprine have been 
shown to be capable of essentially identical roles 
implies that sweeping improvements in clinical im-
munosuppression probably will not be made possi-
ble by the wider routine use of cyclophosphamide. 
Instead, the most important immcdiate use for cy-
clophosphamide in most established transplanta-
tion centers will probably prove to be a potent 
replacement for azathioprine for special indica-
tions. Although azathioprine has been remarkably 
free of side reactions, the suspicion of liver injuryor 
other forms of toxicity should warrant its discon-
tinuance and a trial of cyclophosphamide as a 
diagnostic procedure. In several of our patients, 
derangements in liver function were thereby im-
proved, and in another recipient, a high fever of 
unexplained cause disappeared within a few days. 
I t is our intention to continue to use azathioprine 
as a primary immunosuppressant in many future 
instances of renal and cardiac homotransplanta-
tion, if only because of the acquisition of ten years of 
satisfactory experience with this agent. In view of 
the encouraging results, it is also planned to con-
tinue the evaluation of cyclophosphamide in such 
new recipients. Moreover, a substantial number of 
patients undergoing liver transplantation will be 
given cyclophosphamide from the beginning. After 
liver transplantation, it is crucial as well as excep-
tionally difficult to distinguish homograft rejection 
from other causes of postoperative hepatic dysfunc-
tion of which drug toxicity, biliary duct obstruc-
tion, and viral hepatitis are the most important. 
The use of an agent which has little known intrinsic 
hepatotoxicity in these recipients will carry an 
obvious advantage. 
SUMMARY 
Cyclophosphamide in conjunction with predni-
sone and horse antilymphocyte globulin was ad-
ministered daily in low dosages as a primary 
immunosuppressant to 40 recipients of 37 kidneys, 
six livers and one heart. Rejection was controlled 
with about the same frequency and effectiveness as 
in a companion series of 31 recipients of kidneys or 
livers who were treated in the same way except that 
azathioprine was used instead of cyclophospha-
mide. The incidence of side-effects, including bone 
marrow depression, serious infection, and gastro-
intestinal morbidity, was not significantly different 
with these two agents. 
Fifty-four additional patients including 49, four, 
and one recipients of kidneys, livers, and a heart, 
respectively, had therapy with azathioprine dis-
continued and cyclophosphamide was begun from 
one and one-half to 94 months after transplanta-
tion. Since the antilymphocyte globulin injections 
usually had been stopped earlier, the drug switch in 
the majority of patients was made when the only 
other immunosuppressive agent being used was 
prednisone. Subsequent to the drug change, the 
clinical courses usually were not obviously different 
from those preceding the substitution. In a few in-
stances in which hepatic dysfunction or fever were 
present, these abnormalities resolved. 
These studies have demonstrated that cyclophos-
phamide is an immunosuppressant with a potency, 
safety, and therapeutic role similar to that of 
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azathioprine. Since these two cytotoxic agents are 
thought to act at different phases of the cell cycle, 
the fact that they can be used interchangeably is of 
theoretic interest. From a practical point of view, 
the findings indicate that either agent can serve 
as the cornerstone for combination drug therapy 
and that substitution of one for the other can be 
freely considered if there is suspicion of specific 
pharmacologic toxicity. 
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